Neglected Tropical Diseases (NTDs) are a group of 17 diseases that disproportionally impact those living in poverty. More than 1.4 billion people worldwide are affected by NTDs, including more than 500 million children. The opportunity exists to help millions of people avoid significant debilitation and disability, including malnutrition, disfigurement and social discrimination.
GlaxoSmithKline has an R&D facility in Tres Cantos, Spain, which has been dedicated to developing new treatments to combat diseases of the developing world (DDW) since it was established in 2001. Since that time, GSK has worked in a number of Public Private Partnerships (PPPs) with more than 100 scientists at the site partly funded by GSK's partners. In 2010, GSK announced its intention to open up the Tres Cantos facility further, to become a global centre of excellence that brings new partners to the facility and stimulates research and collaboration on neglected diseases where research is still too fragmented.
To facilitate the establishment of the Tres Cantos Open Lab Foundation, GSK provided £5 million of an initial investment to support the Foundation’s objectives. In October 2012, two years after the Tres Cantos Open Lab Foundation was first established, GSK announced that it would double its funding by making an additional £5m available thus reinforcing its commitment to the value of openness and collaboration. Other projects are supported by partners such as the Bill & Melinda Gates Foundation.
Since the open lab was established in 2013, a portfolio of 35 research projects has been established, one-third of which are now complete. The majority of the projects are supported by the Tres Cantos Open Lab Foundation, a charity established with GBP 10 million in funding from GSK. Other projects are supported by partners such as the Bill & Melinda Gates Foundation.
|Value||GBP 5 Million|